The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Viral vectors: from virology to transgene expression
Open accessAbstract
In the late 1970s, it was predicted that gene therapy would be applied to humans within a decade. However, despite some success, gene therapy has still not become a routine practise in medicine. In this review, we will examine the problems, both experimental and clinical, associated with the use of viral material for transgenic insertion. We shall also discuss the development of viral vectors involving the most important vector types derived from retroviruses, adenoviruses, herpes simplex viruses and adeno‐associated viruses. This article is part of a themed section on Vector Design and Drug Delivery. For a list of all articles in this section see the end of this paper, or visit: http://www3.interscience.wiley.com/journal/121548564/issueyear?year=2009
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903
Raper, S. E., Chirmule, N., Lee, F. S., Wivel, N. A., Bagg, A., Gao, G.-P., Wilson, J. M., & Batshaw, M. L. (2003) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.08.016 · Cited by 1,498
Burns, J. C., Friedmann, T., Driever, W., Burrascano, M., & Yee, J. K. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8033 · Cited by 1,399
Rosenberg, S. A., Aebersold, P., Cornetta, K., Kasid, A., Morgan, R. A., Moen, R., Karson, E. M., Lotze, M. T., Yang, J. C., Topalian, S. L., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199008303230904 · Cited by 1,318
Sustained Correction of X-Linked Severe Combined Immunodeficiency by ex Vivo Gene Therapy
Hacein-Bey-Abina, S., Le Deist, F., Carlier, F., Bouneaud, C., Hue, C., De Villartay, J.-P., Thrasher, A. J., Wulffraat, N., Sorensen, R., Dupuis-Girod, S., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012616 · Cited by 1,058
Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning
Aiuti, A., Slavin, S., Aker, M., Ficara, F., Deola, S., Mortellaro, A., Morecki, S., Andolfi, G., Tabucchi, A., Carlucci, F., et al. (2002) · Science · doi:10.1126/science.1070104 · Cited by 975
Adeno-associated Virus Serotypes: Vector Toolkit for Human Gene Therapy
Wu, Z., Asokan, A., & Samulski, R. J. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.009 · Cited by 922
Chung, J. H., Whiteley, M., & Felsenfeld, G. (1993) · Cell · doi:10.1016/0092-8674(93)80052-g · Cited by 854
Rabinowitz, J. E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., & Samulski, R. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.2.791-801.2002 · Cited by 762
Parks, R. J., Chen, L., Anton, M., Sankar, U., Rudnicki, M. A., & Graham, F. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13565 · Cited by 725
Montini, E., Cesana, D., Schmidt, M., Sanvito, F., Ponzoni, M., Bartholomae, C., Sergi, L. S., Benedicenti, F., Ambrosi, A., Di Serio, C., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1216 · Cited by 701
Engineering targeted viral vectors for gene therapy
Waehler, R., Russell, S. J., & Curiel, D. T. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2141 · Cited by 687
High-titer packaging cells producing recombinant retroviruses resistant to human serum
Cosset, F. L., Takeuchi, Y., Battini, J. L., Weiss, R. A., & Collins, M. K. (1995) · Journal of Virology · doi:10.1128/jvi.69.12.7430-7436.1995 · Cited by 661
Self-citationSelf-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells.
Yu, S. F., von Rüden, T., Kantoff, P. W., Garber, C., Seiberg, M., Rüther, U., Anderson, W. F., Wagner, E. F., & Gilboa, E. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.10.3194 · Cited by 541
Duan, D., Sharma, P., Yang, J., Yue, Y., Dudus, L., Zhang, Y., Fisher, K. J., & Engelhardt, J. F. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8568-8577.1998 · Cited by 522
Nakai, H., Yant, S. R., Storm, T. A., Fuess, S., Meuse, L., & Kay, M. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6969-6976.2001 · Cited by 478
Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2
Girod, A., Ried, M., Wobus, C., Lahm, H., Leike, K., Kleinschmidt, J., Deléage, G., & Hallek, M. (1999) · Nature Medicine · doi:10.1038/12491 · Cited by 405
Characterization of the chicken β-globin insulator
Chung, J. H., Bell, A. C., & Felsenfeld, G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.575 · Cited by 386
Silencing and Variegation of Gammaretrovirus and Lentivirus Vectors
Ellis, J. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1241 · Cited by 379
Improved Methods of Retroviral Vector Transduction and Production for Gene Therapy
Kotani, H., Newton, P. B., Zhang, S., Chiang, Y. L., Otto, E., Weaver, L., Blaese, R. M., Anderson, W. F., & McGarrity, G. J. (1994) · Human Gene Therapy · doi:10.1089/hum.1994.5.1-19 · Cited by 370
Efficient Gene Transfer into Human CD34 + Cells by a Retargeted Adenovirus Vector
Shayakhmetov, D. M., Papayannopoulou, T., Stamatoyannopoulos, G., & Lieber, A. (2000) · Journal of Virology · doi:10.1128/jvi.74.6.2567-2583.2000 · Cited by 367
Mutagenesis and Oncogenesis by Chromosomal Insertion of Gene Transfer Vectors
Baum, C., Kustikova, O., Modlich, U., Li, Z., & Fehse, B. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.253 · Cited by 360
Wool-Lewis, R. J., & Bates, P. (1998) · Journal of Virology · doi:10.1128/jvi.72.4.3155-3160.1998 · Cited by 357
Computational redesign of endonuclease DNA binding and cleavage specificity
Ashworth, J., Havranek, J. J., Duarte, C. M., Sussman, D., Monnat, R. J., Stoddard, B. L., & Baker, D. (2006) · Nature · doi:10.1038/nature04818 · Cited by 345
Immune Responses to AAV in Clinical Trials
Mingozzi, F., & A. High, K. (2011) · Current Gene Therapy · doi:10.2174/156652311796150354 · Cited by 324
Mochizuki, H., Schwartz, J. P., Tanaka, K., Brady, R. O., & Reiser, J. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8873-8883.1998 · Cited by 308
Kobinger, G. P., Weiner, D. J., Yu, Q.-C., & Wilson, J. M. (2001) · Nature Biotechnology · doi:10.1038/85664 · Cited by 307
Sandrin, V., Boson, B., Salmon, P., Gay, W., Nègre, D., Le Grand, R., Trono, D., & Cosset, F.-L. (2002) · Blood · doi:10.1182/blood-2001-11-0042 · Cited by 305
Self-citationRegulatable gene expression systems for gene therapy applications: progress and future challenges
Goverdhana, S., Puntel, M., Xiong, W., Zirger, J. M., Barcia, C., Curtin, J. F., Soffer, E. B., Mondkar, S., King, G. D., Hu, J., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.03.022 · Cited by 283
Cell culture assays reveal the importance of retroviral vector design for insertional genotoxicity
Modlich, U., Bohne, J., Schmidt, M., von Kalle, C., Knöss, S., Schambach, A., & Baum, C. (2006) · Blood · doi:10.1182/blood-2005-08-024976 · Cited by 278
Meganucleases and DNA Double-Strand Break-Induced Recombination: Perspectives for Gene Therapy
Paques, F., & Duchateau, P. (2007) · Current Gene Therapy · doi:10.2174/156652307779940216 · Cited by 273
Hot spots of retroviral integration in human CD34+ hematopoietic cells
Cattoglio, C., Facchini, G., Sartori, D., Antonelli, A., Miccio, A., Cassani, B., Schmidt, M., von Kalle, C., Howe, S., Thrasher, A. J., et al. (2007) · Blood · doi:10.1182/blood-2007-01-068759 · Cited by 270
Shimotohno, K., & Temin, H. M. (1981) · Cell · doi:10.1016/0092-8674(81)90034-9 · Cited by 245
Wei, C. M., Gibson, M., Spear, P. G., & Scolnick, E. M. (1981) · Journal of Virology · doi:10.1128/jvi.39.3.935-944.1981 · Cited by 239
Immune Responses to AAV in Clinical Trials
Mingozzi, F., & High, K. (2007) · Current Gene Therapy · doi:10.2174/156652307782151425 · Cited by 238
Integration Specificity of Phage ϕC31 Integrase in the Human Genome
Chalberg, T. W., Portlock, J. L., Olivares, E. C., Thyagarajan, B., Kirby, P. J., Hillman, R. T., Hoelters, J., & Calos, M. P. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.11.098 · Cited by 237
Wu, Z., Asokan, A., Grieger, J. C., Govindasamy, L., Agbandje-McKenna, M., & Samulski, R. J. (2006) · Journal of Virology · doi:10.1128/jvi.01288-06 · Cited by 237
Mok, H., Palmer, D. J., Ng, P., & Barry, M. A. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.09.015 · Cited by 232
Takeuchi, Y., Cosset, F. L., Lachmann, P. J., Okada, H., Weiss, R. A., & Collins, M. K. (1994) · Journal of Virology · doi:10.1128/jvi.68.12.8001-8007.1994 · Cited by 229
Self-citationVSV-G Pseudotyped Lentiviral Vector Particles Produced in Human Cells Are Inactivated by Human Serum
DePolo, N. J., Reed, J. D., Sheridan, P. L., Townsend, K., Sauter, S. L., Jolly, D. J., & Dubensky, T. W. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0116 · Cited by 220
Current Advances and Future Challenges in Adenoviral Vector Biology and Targeting
Campos, S., & Barry, M. (2007) · Current Gene Therapy · doi:10.2174/156652307780859062 · Cited by 210
Rivella, S., Callegari, J., May, C., Tan, C., & Sadelain, M. (2000) · Journal of Virology · doi:10.1128/.74.10.4679-4687.2000 · Cited by 201
Saeki, Y., Fraefel, C., Ichikawa, T., Breakefield, X. O., & Chiocca, E. A. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0294 · Cited by 195
The influence of adenovirus fiber structure and function on vector development for gene therapy
Nicklin, S. A., Wu, E., Nemerow, G. R., & Baker, A. H. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.05.008 · Cited by 184
Immunity to adeno-associated virus vectors in animals and humans: a continued challenge
Zaiss, A. K., & Muruve, D. A. (2008) · Gene Therapy · doi:10.1038/gt.2008.54 · Cited by 180
Thornhill, S. I., Schambach, A., Howe, S. J., Ulaganathan, M., Grassman, E., Williams, D., Schiedlmeier, B., Sebire, N. J., Gaspar, H. B., Kinnon, C., et al. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300393 · Cited by 166
Ghosh, A., Yue, Y., Lai, Y., & Duan, D. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300322 · Cited by 161
Tabin, C. J., Hoffmann, J. W., Goff, S. P., & Weinberg, R. A. (1982) · Molecular and Cellular Biology · doi:10.1128/mcb.2.4.426 · Cited by 160
Precise hit: adeno-associated virus in gene targeting
Vasileva, A., & Jessberger, R. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1266 · Cited by 157
Adenovirus Type 5 Interactions with Human Blood Cells May Compromise Systemic Delivery
Lyons, M. J., Onion, D., Green, N. K., Aslan, K., Rajaratnam, R., Bazán‐Peregrino, M., PHIPPS, S. L., Hale, S. J. M., Mautner, V., Seymour, L. W., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.003 · Cited by 156
Gene therapy: X-SCID transgene leukaemogenicity
Thrasher, A., Gaspar, H. B., Baum, C., Modlich, U., Schambach, A., Candotti, F., Otsu, M., Sorrentino, B., Scobie, L., Cameron, E., et al. (2006) · Nature · doi:10.1038/nature05219 · Cited by 155
Croyle, M. A., Callahan, S. M., Auricchio, A., Schumer, G., Linse, K. D., Wilson, J. M., Brunner, L. J., & Kobinger, G. (2003) · Journal of Virology · doi:10.1128/jvi.78.2.912-921.2004 · Cited by 152
Retroviral vectors for human gene delivery
McTaggart, S., & Al‐Rubeai, M. (2002) · Biotechnology Advances · doi:10.1016/s0734-9750(01)00087-8 · Cited by 137
Endocytosis of adenovirus and adenovirus capsid proteins
Medina‐Kauwe, L. K. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.07.010 · Cited by 136
Perabò, L., Goldnau, D., White, K., Endell, J., Bouças, J., Humme, S., Work, L. M., Janicki, H., Hallek, M. J., Baker, A. H., et al. (2006) · Journal of Virology · doi:10.1128/jvi.00076-06 · Cited by 136
Erratum: Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2
Girod, A., Ried, M. U., Wobus, C., Lahm, H., Leike, K., Kleinschmidt, J., Deléage, G., & Hallek, M. J. (1999) · Nature Medicine · doi:10.1038/71021 · Cited by 136
Lentiviral vectors: optimization of packaging, transduction and gene expression
Delenda, C. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.501 · Cited by 135
Kelly, P. F., Vandergriff, J. A., Nathwani, A. C., Nienhuis, A. W., & Vanin, E. F. (2000) · Blood · doi:10.1182/blood.v96.4.1206 · Cited by 134
Antibody-Directed Targeting of Retroviral Vectors via Cell Surface Antigens
Morizono, K., Bristol, G. C., Xie, Y., Kung, S. K. P., & Chen, I. S. Y. (2001) · Journal of Virology · doi:10.1128/jvi.75.17.8016-8020.2001 · Cited by 132
Lack of Site-Specific Integration of the Recombinant Adeno-Associated Virus 2 Genomes in Human Cells
Ponnazhagan, S., Erikson, D., Kearns, W. G., Zhou, S. Z., Nahreini, P., Wang, X.-S., & Srtvastava, A. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.3-275 · Cited by 130
In Vivo Correction of Murine Hereditary Tyrosinemia Type I by ϕC31 Integrase-Mediated Gene Delivery
Held, P. K., Olivares, E. C., Aguilar, C., Finegold, M. J., Calos, M. P., & Grompe, M. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.11.001 · Cited by 129
Improving Transcriptional Termination of Self-inactivating Gamma-retroviral and Lentiviral Vectors
Schambach, A., Galla, M., Maetzig, T., Loew, R., & Baum, C. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300152 · Cited by 127
Croyle, M. A., Le, H. T., Linse, K. D., Cerullo, V., Toietta, G., Beaudet, A. L., & Pastore, L. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302441 · Cited by 125
Progress in Adeno-Associated Virus Type 2 Vector Production: Promises and Prospects for Clinical Use
Grimm, D., & Kleinschmidt, J. A. (1999) · Human Gene Therapy · doi:10.1089/10430349950016799 · Cited by 125
Nunes, F. A., Furth, E. E., Wilson, J. M., & Raper, S. E. (1999) · Human Gene Therapy · doi:10.1089/10430349950016852 · Cited by 121
Verhoeyen, E., Dardalhon, V., Ducrey, O., Trono, D., Taylor, N. N., & Cosset, F. (2003) · Blood · doi:10.1182/blood-2002-07-2224 · Cited by 121
Self-citationProduction and Neurotropism of Lentivirus Vectors Pseudotyped with Lyssavirus Envelope Glycoproteins
Desmaris, N., Bosch, A., Salaün, C., Petit, C., Prévost, M., Tordo, N., Perrin, P., Schwartz, O., de ROCQUIGNY, H., & Heard, J. M. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0431 · Cited by 121
Sinn, P. L., Hickey, M. A., Staber, P. D., Dylla, D. E., Jeffers, S. A., Davidson, B. L., Sanders, D. A., & McCray, P. B. (2003) · Journal of Virology · doi:10.1128/jvi.77.10.5902-5910.2003 · Cited by 118
State-of-the-art of the production of retroviral vectors
Merten, O. W. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.499 · Cited by 117
Directed evolution of a recombinase for improved genomic integration at a native human sequence
Sclimenti, C. R. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.24.5044 · Cited by 112
Large-Scale Processing of Recombinant Retroviruses for Gene Therapy
Andreadis, S. T., Roth, C. M., Doux, J. M. L., Morgan, J. R., & Yarmush, M. L. (1999) · Biotechnology Progress · doi:10.1021/bp980106m · Cited by 108
Tissue-specific promoters for cancer gene therapy
Saukkonen, K., & Hemminki, A. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.5.683 · Cited by 108
Maurice, M., Verhoeyen, E., Salmon, P., Trono, D., Russell, S. J., & Cosset, F. (2002) · Blood · doi:10.1182/blood.v99.7.2342 · Cited by 107
Self-citationGene targeting in vivo by adeno‐associated virus vectors
Miller, D. G., Wang, P.-R., Petek, L. M., Hirata, R. K., Sands, M. S., & Russell, D. W. (2006) · Nature Biotechnology · doi:10.1038/nbt1231 · Cited by 105
Targeting Retroviral and Lentiviral Vectors
Sandrin, V., Russell, S. J., & Cosset, F. (2003) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-19012-4_4 · Cited by 101
Self-citationWade‐Martins, R., Saeki, Y., & Chiocca, E. A. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00060-1 · Cited by 97
Eto, Y., Gao, J., Sekiguchi, F., Kurachi, S., Katayama, K., Maeda, M., Kawasaki, K., Mizuguchi, H., Hayakawa, T., Tsutsumi, Y. M., et al. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.699 · Cited by 96
Tan, W., Dong, Z., Wilkinson, T. A., Barbas, C. F., & Chow, S. A. (2006) · Journal of Virology · doi:10.1128/jvi.80.4.1939-1948.2006 · Cited by 90
Sandrin, V., Muriaux, D. M., Darlix, J., & Cosset, F. (2004) · Journal of Virology · doi:10.1128/jvi.78.13.7153-7164.2004 · Cited by 86
Self-citationPeng, K.-W., Pham, L., Ye, H., Zufferey, R., Trono, D., Cosset, F., & Russell, S. J. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301552 · Cited by 84
Self-citationA Look to Future Directions in Gene Therapy Research for Monogenic Diseases
Porteus, M. H., Connelly, J. P., & Pruett‐Miller, S. M. (2006) · PLoS Genetics · doi:10.1371/journal.pgen.0020133 · Cited by 81
Dong, J., Roth, M. G., & Hunter, E. (1992) · Journal of Virology · doi:10.1128/jvi.66.12.7374-7382.1992 · Cited by 77
Suomalainen, M., & Garoff, H. (1994) · Journal of Virology · doi:10.1128/jvi.68.8.4879-4889.1994 · Cited by 77
Rogers, S., Löwenthal, A., Terheggen, H. G., & Columbo, J. P. (1973) · The Journal of Experimental Medicine · doi:10.1084/jem.137.4.1091 · Cited by 77
Efficient Whole-body Transduction with Trans-splicing Adeno-associated Viral Vectors
Ghosh, A., Yue, Y., Long, C., Bostick, B., & Duan, D. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300081 · Cited by 76
Efficient Whole-body Transduction with Trans-splicing Adeno-associated Viral Vectors
Ghosh, A., Yue, Y., Long, C., Bostick, B., & Duan, D. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300153 · Cited by 73
Surface-engineering of lentiviral vectors
Verhoeyen, E., & Cosset, F. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.494 · Cited by 71
Self-citationZaupa, C., Revol, V., & Epstein, A. L. (2003) · Human Gene Therapy · doi:10.1089/104303403322124774 · Cited by 67
Peng, K.-W., Vile, R. G., Cosset, F., & Russell, S. J. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300982 · Cited by 66
Self-citationImproving rAAV production and purification: towards the definition of a scaleable process
Blouin, V., Brument, N., Toublanc, E., Raimbaud, I., Moullier, P., & Salvetti, A. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.505 · Cited by 65
Integration Site Selection by Lentiviruses: Biology and Possible Control
Bushman, F. D. (2002) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-56114-6_8 · Cited by 63
Retrovirus Silencing and Vector Design: Relevance to Normal and Cancer Stem Cells?
Ellis, J., & Yao, S. (2005) · Current Gene Therapy · doi:10.2174/1566523054546233 · Cited by 62
Relationship between Retroviral DNA Integration and Gene Expression
Weidhaas, J. B., Angelichio, E. L., Fenner, S., & Coffin, J. M. (2000) · Journal of Virology · doi:10.1128/jvi.74.18.8382-8389.2000 · Cited by 60
Emerging Adenoviral Vectors for Stable Correction of Genetic Disorders
Jager, L., & Ehrhardt, A. (2007) · Current Gene Therapy · doi:10.2174/156652307781369074 · Cited by 57 · cited 1×
“The recent emergence of adenoviral vectors for stable correction of genetic disorders is discussed by Jager and Ehrhardt (2007).”
BackgroundFoamy Virus Vectors: An Awaited Alternative to Gammaretro- and Lentiviral Vectors
Rethwilm, A. (2007) · Current Gene Therapy · doi:10.2174/156652307781369092 · Cited by 57
Expanding Adeno-associated Viral Vector Capacity: A Tale of Two Vectors
Ghosh, A., & Duan, D. (2007) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2007.10648098 · Cited by 54
Hatziioannou, T., Delahaye, E., Martin, F., Russell, S. J., & Cosset, F. (1999) · Human Gene Therapy · doi:10.1089/10430349950017860 · Cited by 54
Self-citationHatziioannou, T., Valsesia‐Wittmann, S., Russell, S. J., & Cosset, F. (1998) · Journal of Virology · doi:10.1128/jvi.72.6.5313-5317.1998 · Cited by 53
Self-citationOptimized conditions for the production of recombinant amphotropic retroviral vector preparations
Kaptein, L. C. M., Greijer, A. E., Valerio, D., & van Beusechem, V. (1997) · Gene Therapy · doi:10.1038/sj.gt.3300373 · Cited by 51
AAV vectors and tumorigenicity
Kay, M. A. (2007) · Nature Biotechnology · doi:10.1038/nbt1007-1111 · Cited by 50
Site‐Specific Integration with ϕC31 Integrase for Prolonged Expression of Therapeutic Genes
Ginsburg, D. S., & Calos, M. P. (2005) · Advances in genetics · doi:10.1016/s0065-2660(05)54008-2 · Cited by 48
Schauber, C., Simmons, A. D., Tuerk, M. J., Pacheco, C. D., & Veres, G. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302399 · Cited by 48
Denby, L., Work, L. M., Seggern, D. J. V., Wu, E. Y., McVey, J. H., Nicklin, S. A., & Baker, A. H. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300214 · Cited by 47
Cuchet, D., Potel, C., Thomas, J., & Epstein, A. L. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.7.975 · Cited by 47
Verhoeyen, E., Wiznerowicz, M., Olivier, D., Izac, B., Trono, D., Dubart‐Kupperschmitt, A., & Cosset, F. (2005) · Blood · doi:10.1182/blood-2004-12-4736 · Cited by 40
Self-citationCortés, M. L., Oehmig, A., Saydam, O., Sanford, J. D., Perry, K. F., Fraefel, C., & Breakefield, X. O. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300338 · Cited by 37
Ishikawa, Y., Tanaka, N., Murakami, K., Uchiyama, T., Kumaki, S., Tsuchiya, S., Kugoh, H., Oshimura, M., Calos, M. P., & Sugamura, K. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.891 · Cited by 37
Loewen, N. A., Leske, D. A., Chen, Y., Teo, W., Saenz, D. T., Peretz, M., Holmes, J. M., & Poeschla, E. M. (2003) · The Journal of Gene Medicine · doi:10.1002/jgm.447 · Cited by 35
Szécsi, J., Drury, R., Josserand, V., Grange, M.-P., Boson, B., Hartl, I., Schneider, R. M., Buchholz, C. J., Coll, J., Russell, S. J., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.04.007 · Cited by 34
Self-citationGuibinga, G.-H., Hall, F. L., Gordon, E. M., Ruoslahti, E. I., & Friedmann, T. (2003) · Molecular Therapy · doi:10.1016/j.ymthe.2003.09.018 · Cited by 30
Bouard, D., Sandrin, V., Boson, B., Négre, D., Thomas, G., Granier, C., & Cosset, F. (2007) · Traffic · doi:10.1111/j.1600-0854.2007.00581.x · Cited by 29
Self-citationRentsendorj, A., Xie, J., MacVeigh, M., Agadjanian, H., Bass, S., Kim, D.-H., Rossi, J., Hamm‐Alvarez, S. F., & Medina‐Kauwe, L. K. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302729 · Cited by 27
Guibinga, G.-H., & Friedmann, T. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.12.002 · Cited by 27
Chimeric Herpes Simplex Virus/Adeno-Associated Virus Amplicon Vectors
Glauser, D. L., Ackermann, M., Saydam, O., & Fraefel, C. (2006) · Current Gene Therapy · doi:10.2174/156652306777592090 · Cited by 23
Pseudotype Formation of Moloney Murine Leukemia Virus with Sendai Virus Glycoprotein F
Spiegel, M., Bitzer, M., Schenk, A., Rossmann, H., Neubert, W. J., Seidler, U. E., Gregor, M., & Lauer, U. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.6.5296-5302.1998 · Cited by 21
Advanced Targeting Strategies for Murine Retroviral and Adeno-associated Viral Vectors
Yu, J. H., & Schaffer, D. V. (2005) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_006 · Cited by 20
Constructing the Vertebrate Genome
Bushman, F. D. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00747-5 · Cited by 2
Cited by
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
mRNA vaccine delivery using lipid nanoparticles
Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R., & Blankschtein, D. (2016) · Therapeutic Delivery · doi:10.4155/tde-2016-0006 · Cited by 624
Delivery technologies for genome editing
Yin, H., Kauffman, K. J., & Anderson, D. G. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.280 · Cited by 597
New Vaccine Technologies to Combat Outbreak Situations
Rauch, S., Jasny, E., Schmidt, K. E., & Petsch, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01963 · Cited by 579
Gene therapy and DNA delivery systems
Ibraheem, D., Elaissari, A., & Fessi, H. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.11.041 · Cited by 454
Metadata
- Authors
- Bouard, D., Alazard‐Dany, N., & Cosset, F.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2009-04-28
- Volume
- 157
- Issue
- 2
- Pages
- 153-165
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1508974207
- Cited by
- 360
- References
- 117
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.